Introduction
Dual antiplatelet therapy (DAPT), a combination of aspirin and either clopidogrel, prasugrel or ticagrelor, is recommended for secondary prevention of ischaemic events in coronary artery disease in both patients managed medically and those undergoing percutaneous coronary intervention (PCI). Patients taking DAPT may be at high bleed risk if other factors are present, such as older age, kidney and/or liver disease, active cancer, anaemia, low platelet count, previous stroke, prior bleeding, recent trauma or surgery, and use of oral anticoagulants and/or non-steroidal anti-inflammatory drugs (NSAIDs).1 Gastrointestinal (GI) bleedin
